Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current and future use of positron emission tomography (PET) in breast cancer.

Literature DB >> 17075687

Current and future use of positron emission tomography (PET) in breast cancer.

Abstract

Positron emission tomography (PET) is a radiotracer imaging method that is increasingly used in both the clinical care of breast cancer patients and in translational breast cancer research. This review emphasizes current and future clinical applications of PET to breast cancer, and highlights some translational research using PET to elucidate the clinical biology of breast cancer. PET principles are reviewed, followed by a review of current applications of (18)F-fluorodeoxyglucose (FDG) to clinical breast cancer care. Finally we review work done with other radiopharmaceuticals beyond FDG designed to image a number of aspects of breast cancer biology, emphasizing those most likely to enter clinical trials in the near future.

Entities: Chemical Disease Species

Mesh：

Substances：
Fluorodeoxyglucose F18

Year: 2006 PMID： 17075687 DOI： 10.1007/s10911-006-9019-z

Source DB: PubMed Journal: J Mammary Gland Biol Neoplasia ISSN： 1083-3021 Impact factor: 2.673

86 in total

1. Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method?

Authors: David A Mankoff; Mark Muzi; Kenneth A Krohn
Journal: Mol Imaging Biol Date: 2003 Sep-Oct Impact factor: 3.488

2. Imaging of apoptosis (programmed cell death) with 99mTc annexin V.

Authors: F G Blankenberg; P D Katsikis; J F Tait; R E Davis; L Naumovski; K Ohtsuki; S Kopiwoda; M J Abrams; H W Strauss
Journal: J Nucl Med Date: 1999-01 Impact factor: 10.057

Review 3. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.

Authors: Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce O'shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan
Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531

Review 4. Defining apoptosis.

Authors: D Hockenbery
Journal: Am J Pathol Date: 1995-01 Impact factor: 4.307

Review 5. Evolving role of positron emission tomography in breast cancer imaging.

Authors: William B Eubank; David A Mankoff
Journal: Semin Nucl Med Date: 2005-04 Impact factor: 4.446

6. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

Authors: N Avril; M Menzel; J Dose; M Schelling; W Weber; F Jänicke; W Nathrath; M Schwaiger
Journal: J Nucl Med Date: 2001-01 Impact factor: 10.057

7. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Authors: David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Aaron Charlop; Thomas J Lawton; Erin K Schubert; Jeffrey Tseng; Robert B Livingston
Journal: J Nucl Med Date: 2002-04 Impact factor: 10.057

Review 8. Imaging hypoxia and angiogenesis in tumors.

Authors: Joseph G Rajendran; Kenneth A Krohn
Journal: Radiol Clin North Am Date: 2005-01 Impact factor: 2.303

9. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).

Authors: Jennifer R Bellon; Robert B Livingston; William B Eubank; Julie R Gralow; Georgiana K Ellis; Lisa K Dunnwald; David A Mankoff
Journal: Am J Clin Oncol Date: 2004-08 Impact factor: 2.339

Review 10. Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer.

Authors: F Berger; S S Gambhir
Journal: Breast Cancer Res Date: 2000-12-11 Impact factor: 6.466

3 in total